Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q3 FY26 results · Oct–Dec 2025
Neuland Laboratories reported revenue from operations of ₹439.71 crore (up 10.5% from Q3 FY25) and net profit of ₹40.57 crore (down 60.1% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 439.71 | 398.03 | +10.5% | 514.27 | −14.5% |
| Other income | 8.05 | 3.91 | +106.2% | 1.80 | +347.4% |
| Total income | 447.76 | 401.94 | +11.4% | 516.07 | −13.2% |
| Profit before tax | 54.48 | 127.76 | −57.4% | 129.44 | −57.9% |
| Net profit for the period | 40.57 | 101.59 | −60.1% | 96.85 | −58.1% |
| EPS, basic (₹) | 31.62 | 79.18 | −60.1% | 75.49 | −58.1% |
| Net margin (%) | 9.2 | 25.5 | 18.8 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 439.71 | 398.03 | +10.5% | 514.27 | −14.5% |
| Other income | 8.05 | 3.91 | +106.2% | 1.80 | +347.7% |
| Total income | 447.76 | 401.94 | +11.4% | 516.07 | −13.2% |
| Profit before tax | 54.27 | 127.54 | −57.4% | 129.04 | −57.9% |
| Net profit for the period | 40.42 | 101.39 | −60.1% | 96.46 | −58.1% |
| EPS, basic (₹) | 31.50 | 79.03 | −60.1% | 75.18 | −58.1% |
| Net margin (%) | 9.2 | 25.5 | 18.8 |
Consolidated
- Filed with BSE
- 09 Feb 2026, 16:53 IST
- Board meeting
- 09 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Feb 2026, 16:53 IST
- Board meeting
- 09 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE